Cécile Dorange

Showing 1-12 of 12 articles

Author Alexandre Abizaid

The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled

Abizaid A, Costa Jr J, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong W-F, Sudhir K, Serruys P

April 20, 2015 | 10.4244/EIJV10I12A243

Author Christos Bourantas

Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial

Bourantas C, Farooq V, Zhang Y-J, Muramatsu T, Gogas B, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Dorange C, Rapoza R, Onuma Y, Garcia-Garcia H, Serruys P

March 20, 2015 | 10.4244/EIJY14M04_11

Author Cihan Simsek

Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH)

Simsek C, Magro M, Onuma Y, Boersma E, Smits P, Dorange C, Veldhof S, Regar E, Serruys P, van Geuns R

June 20, 2014 | 10.4244/EIJV10I2A38

Author Patrick Serruys

Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months

Serruys P, Onuma Y, Garcia-Garcia H, Muramatsu T, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert K, Rapoza R, Ormiston J

March 20, 2014 | 10.4244/EIJV9I11A217

Author Bill D. Gogas

The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials

Gogas B, Bourantas C, Garcia-Garcia H, Onuma Y, Muramatsu T, Farooq V, Diletti R, van Geuns R, De Bruyne B, Chevalier B, Thuesen L, Smits P, Dudek D, Koolen J, Windecker S, Whitbourn R, McClean D, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Ormiston J, Serruys P

October 25, 2013 | 10.4244/EIJV9I6A115

Author Josep Gomez-Lara

Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study

Gomez-Lara J, Diletti R, Brugaletta S, Onuma Y, Farooq V, Thuesen L, McClean D, Koolen J, Ormiston J, Windecker S, Whitbourn R, Dudek D, Dorange C, Veldhof S, Rapoza R, Regar E, Garcia-Garcia H, Serruys P

June 27, 2012

Author Salvatore Brugaletta

Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study

Brugaletta S, Garcia-Garcia H, Diletti R, Gomez-Lara J, Garg S, Onuma Y, Shin E, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Dorange C, Veldhof S, Rapoza R, Sudhir K, Bruining N, Ormiston J, Serruys P

April 20, 2011

Author Ahmed A. Khattab

Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial

Khattab A, Richardt G, Verin V, Kelbæk H, Macaya C, Berland J, Miquel-Hebert K, Dorange C, Serruys P

March 20, 2008

Author Peter Ruygrok

One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study

Ruygrok P, Desaga M, Van den Branden B, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys P

November 20, 2007

Author Marcel A.M. Beijk

Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial)

Beijk M, Neumann F-J, Wiemer M, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C, Serruys P, Piek J

August 20, 2007

Author Eberhard Grube

Prospective non-randomized multi-center evaluation of the non-polymer based ACHIEVE™ Paclitaxel Eluting Coronary Stent System in treatment of lesions with high risk of revascularization due to restenosis: the DELIVER II study

Grube E, Gershlick A, Bartorelli A, Buellesfeld L, Blanchard D, Macaya C, Buettner H, Lim V, Boone E, Dorange C, Marco J

February 20, 2006

Author Keiichi Tsuchida

One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings<br />(The SPIRIT FIRST Trial)

Tsuchida K, Piek J, Neumann F-J, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C, Serruys P

November 20, 2005

1

Latest news

EHRA/EAPCI consensus on LAA occlusion, EAPCI Position paper on defining device sucess and more

(3D volume-rendered CCTA LAA example)

January 17, 2020

From Paris to Amsterdam: EuroPCR, ESC 2020 and spotlight on “The Cutting Edge of Cardiology”

January 17, 2020

New this week: Comparing OFR & FFR, Provisional bifurcation stenting procedure and more

January 21, 2020

Access some of the latest Trials: EXCEL 5 years, GALILEO, ISAR-REACT 5 ...

(The Trials book is supported by Biotronik)

January 15, 2020

Guidance Papers

Guidelines, consensus & position papers

The role of the Heart Team in the planning of aortic valve replacement

January 15, 2020

Last week's JAA's: Inferior caval valve implantation for severe tricuspid regurgitation

January 14, 2020

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke